Welcome to InCeltu
Based in Rockville, Maryland, InCeltu, LLC is focused to develop the best RNA in situ detection technology and provides in situ hybridization services to its customers in academia, government, pharma and biotech companies for detection of any RNA targets, including micro RNA, lncRNA, in FFPE tissue sections.
InCeltu’s services are based on its proprietary AccuRISH technology, the best chromogenic in situ hybridization technology that is able to locate and measure any RNA targets, including mRNA, miRNA, siRNA and lincRNA, in situ on FFPE tissue sections at cellular level. InCeltu’s AccuRISH technology produces the highest quality RISH images among its competitors and makes RNA based biomarker and drug discovery easier.
Locate Your RNA Targets with Precision
Our Mission
After the discovery of noncoding RNA, RNA molecules are no longer considered just as communicators between DNA and protein, but also as key regulators in the development of many human diseases. The expression pattern of those disease related RNA molecules can be measured and used as biomarkers to guide the diagnosis and treatment of human diseases in the upcoming personalized medicine.
A key technology for discovery and validation of the next generation RNA biomarkers is RNA in situ hybridization (RISH) for detection of RNA targets in formalin-fixed paraffin-embedded (FFPE) clinical samples. Compare to other detection technologies, RISH is the only one that can reveal the location and expression level of the RNA targets at tissue and cellular level, which is critically related to the development of disease. Compare to PCR, RISH is actually more sensitive that a single positive cell can be detected in a tissue section, no more need for laser capture micro dissection. InCeltu’s AccuRISH technology accelerates the discovery of RNA biomarkers and RNA drugs by providing the best RNA in situ hybridization service to the RNA research community.
Our Vision
RNA molecules, once seen as simple messengers between DNA and proteins, are now recognized as pivotal regulators of human diseases. These molecules, particularly noncoding RNAs, hold immense potential as biomarkers for guiding the diagnosis, prognosis, and treatment of diseases in the era of personalized medicine.
InCeltu’s mission is to advance the discovery and validation of next-generation RNA biomarkers and RNA-based therapeutics by providing the most accurate and reliable RNA in situ hybridization services.
InCeltu, LLC
13, Taft Ct.
Suite 231
Rockville, MD 20850
Tel: 240-406-9368